RxDoctor Payments Data

Annah Vollstedt, MD

Urology · Iowa City, IANPI 1942629274

Payments from drug & device makers

What this record shows

This record is dominated by grants: $60,000 of the $66,079 with a category attached, or 90.8%. Medtronic accounts for 96.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $50,366 and has fallen 97.0% since, to $1,535 in 2025. Among urology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$66,079in general payments, 2019–2025

Across 43 payments — averaging $1536.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$64K
  • Valencia Technologies Corporation$2K
  • Boston Scientific$296
  • Axonics, Inc.$202
  • AbbVie$151
  • Merck$96
  • plus $47 from 1 others
$82,060in research payments, 2019–2025

Across 11 payments — averaging $7460.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$82K

What the payments were for

  • Speaking & faculty fees$2,3404%
  • Grants$60,00091%
  • Travel & lodging$1,7063%
  • Food & beverage$2,0333%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)20$63,749
Valencia Technologies Corporation10$1,539
Boston Scientific6$296
Axonics, Inc.3$202
AbbVie(2 entities)2$151
Merck1$96
Conmed Corporation1$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,079 in reported general payments places this provider in the 95th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$96,781
Medicare patients
385
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron75$63,376
MyrbetriqMirabegron43$41,001
Estradiol152$10,457
Methenamine Hippurate23$1,958
Gentamicin Sulfate38$1,483
Trospium Chloride18$1,405
Oxybutynin Chloride ErOxybutynin Chloride44$1,126
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst45$703
Solifenacin Succinate20$556
Tamsulosin Hcl11$277
Hydroxyzine Hcl15$187
Cephalexin44$176
Terazosin Hcl26$161
Oxybutynin Chloride11$104
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$71

Paid to pharmacies, not to this prescriber.

Other urology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →